Daiichi Sankyo Shutting UK Site As Global Cost Drive Continues
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is taking another step in its worldwide R&D restructuring process by deciding to shut a UK development center near London that will affect around 80 positions.
You may also be interested in...
Daiichi Closing Indian Site As Global Restructuring Continues
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Japan Issues Strong Warning Over Brexit
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.